Metagenomi Therapeutics, Inc. Operating Cash Flow
Metagenomi Therapeutics, Inc. (MGX) reported Operating Cash Flow of -$40.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$19.51M.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$21.18M.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$23.55M.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$21.25M.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$88.89M.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$109.07M.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$91.41M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$40.69M 10-Q · filed 2026-08-10 | -$64.23M derived: sum of 3 quarters · filed 2026-08-10 | -$85.49M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$21.18M 10-Q · filed 2026-05-11 | -$44.72M derived: sum of 2 quarters · filed 2026-05-11 | -$65.97M derived: sum of 3 quarters · filed 2026-05-11 | -$87.22M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$23.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$44.80M derived: sum of 2 quarters · filed 2026-03-05 | -$66.05M derived: sum of 3 quarters · filed 2026-08-10 | -$88.89M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$21.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$42.50M derived: sum of 2 quarters · filed 2026-08-10 | -$65.35M 10-Q · filed 2025-11-12 | -$91.62M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$21.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$44.09M 10-Q · filed 2026-08-10 | -$70.37M derived: sum of 3 quarters · filed 2026-08-10 | -$97.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$22.84M 10-Q · filed 2026-05-11 | -$49.12M derived: sum of 2 quarters · filed 2026-05-11 | -$75.76M derived: sum of 3 quarters · filed 2026-05-11 | -$102.06M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$26.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$52.91M derived: sum of 2 quarters · filed 2026-03-05 | -$79.22M derived: sum of 3 quarters · filed 2026-03-05 | -$109.07M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$26.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$52.95M derived: sum of 2 quarters · filed 2025-11-12 | -$82.80M 10-Q · filed 2025-11-12 | -$103.39M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$26.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$56.16M 10-Q · filed 2025-08-12 | -$76.75M derived: sum of 3 quarters · filed 2025-08-12 | -$100.48M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$29.85M 10-Q · filed 2025-05-13 | -$50.44M derived: sum of 2 quarters · filed 2025-05-13 | -$74.17M derived: sum of 3 quarters · filed 2025-05-13 | -$100.26M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$20.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$44.32M derived: sum of 2 quarters · filed 2025-03-17 | -$70.41M derived: sum of 3 quarters · filed 2025-03-17 | -$91.41M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$23.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$49.82M derived: sum of 2 quarters · filed 2024-11-13 | -$70.82M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$26.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$47.09M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$21.00M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |